New Assay Expands INDIGO’s GPCR Portfolio and Supports Development of Next-Generation CNS-Related Therapeutics STATE ...
Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
A publication from Acta Pharmaceutica Sinica B discusses allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain. Neuropathic pain is a debilitating ...
Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, No. 16 (April 19, 2022), pp. 1-10 (10 pages) Allosteric modulators of G-protein-coupled receptors (GPCRs) ...
A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, ...
The Company will evaluate BNC210 in patients with SAD in the phase 2 PREVAIL trial. The Food and Drug Administration (FDA) has granted Fast Track designation to BNC210 for the acute treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results